An extended expression window

Sail’s eRNA is a translatable circular RNA designed to sustain protein expression longer than conventional mRNA. This extended expression window has the potential to improve dose potency and support superior therapeutic activity across a broader range of diseases and protein types.

eRNA is a form of translatable circular RNA where the contiguous ring of single-stranded RNA lacks the cap and poly-A tail that cells normally use to control mRNA degradation. Its highly modular individual elements enable expression of different types of protein cargo at the intended level of expression and in the desired target cell type.

Conventional mRNA can produce proteins rapidly, but its relatively short expression window may limit the therapeutic applications it can address. eRNA is designed to sustain expression over time while remaining a transient and non-integrating genetic payload. These properties have unlocked uncharted opportunities to develop RNA medicines with greater potency, broader utility, and differentiated therapeutic profiles.

Reaching the cells that matter

Sail’s targeted nanoparticles (TNPs) are designed to deliver eRNA beyond the liver and into selected cells and tissues. By attaching targeting ligands to an optimized nanoparticle core, each TNP can recognize a chosen cell type, enter the cell, and release its eRNA payload.

Targeting ligands direct cargo to the intended cell population, reducing systemic exposure.

Optimized lipid composition supports robust cytoplasmic delivery.

Industry-standard unit operations and established conjugation process to enable efficient platform-based production

Sail’s modular nanoparticle architecture allows targeting ligands to be introduced without rebuilding the core delivery system. This creates a unique opportunity for reaching new cells and tissues, advancing new programs, and building a portfolio of medicines from the same foundational platform technology.

The medicine is our system

The therapeutic potential of an RNA medicine depends on more than its payload or delivery vehicle alone. Sail designs eRNA and targeted nanoparticles together to shape expression, cell selectivity, tissue distribution, dose potency, and therapeutic performance.

This integrated approach, enabled by AI, is the foundation for creating medicines that generate meaningful biology in vivo and can be manufactured and delivered at pharmaceutical scale.

We’re using cutting-edge, proprietary AI techniques and rapid prototyping abilities to accelerate our efforts.

With our programmable eRNA technology and proprietary atlas of programmable nanoparticle components, Sail has dramatically expanded the RNA medicines design space. To interrogate this vast design space, we have built a high-throughput system that generates functional data at remarkable pace to create iterative learning loops that leverage machine intelligence to predictably engineer RNA medicines.

With unmatched data flow and proprietary techniques, we’re able to apply AI to program in an integrated way across the pharmacology and delivery components of the medicine – i.e., RNA and nanoparticle – with the aim of driving breakthroughs in durability, potency, safety/tolerability and targeting – and ultimately delivering therapeutic benefits to patients that have previously been unreachable.